XXXVI Congreso SETH

Ponencias 9 3. La evaluación del riesgo tromboembólico puede ser un fac- tor relevante en la toma de decisiones sobre el tratamiento antineoplásico en las pacientes con cáncer de mama, en particular en lo que respecta a la hormonoterapia, aunque está limitada por la ausencia de escalas validadas de riesgo trombótico en estas pacientes. 4. No se ha demostrado que la aparición de eventos trom- boembólicos, más allá de su impacto en la supervivencia precoz, se asocie a una peor evolución de la neoplasia. El tratamiento anticoagulante con el fin de mejorar la super- vivencia de la neoplasia no está justificado en el cáncer de mama. Bibliografía 1. Harbeck N, Gnant M. Breast cancer. Lancet 2017;389(10074):1134- 50. DOI: 10.1016/S0140-6736(16)31891-8 2. Chew HK, Wun T, Harvey DJ, et al. Incidence of Venous Thromboem- bolism and the Impact on Survival in Breast Cancer Patients. J Clin Oncol 2007;26(1):70-6. DOI: 10.1200/JCO.2006.07.4393 3. Carmona-Bayonas A, Gómez D, Martínez de Castro E, et al. A snaps- hot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry. Eur J Intern Med 2020;(April). DOI: 10.1016/j.ejim.2020.05.031 4. Horsted F, West J, Grainge MJ. Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. PLoS Med 2012;9(7):e1001275. DOI: 10.1371/journal.pmed.1001275 5. Walker AJ, West J, Card TR, et al. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood 2016;127(7):849-57. Doi: 10.1182/ blood-2015-01-625582 6. Tran BH, Joanna Nguyen T, Hwang BH, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast 2013;22(4):444-8. DOI: 10.1016/j.breast.2013.04.018 7. Redana S, Sharp A, Lote H, et al. Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast can- cer: An off study population. Breast 2016;30:13-8. DOI: 10.1016/j. breast.2016.07.019 8. Fisher B, Costantino JP, Lawrence Wickerham D, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyWolmark, and Other National Sur- gical Adjuvant Breast and Bowel Project Investigators. J Natl Cancer Inst 1998;90:1371-88. 9. Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endo- crine therapy and risk of cardiovascular disease in female breast cancer survivors: Systematic review. BMJ 2018;363. DOI: 10.1136/bmj.k3845 10. Gade IL, Braekkan SK, Naess IA, et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandina- vian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost 2017;15(8):1567-75. DOI: 10.1111/jth.13752 11. Thein K, Zaw M, Tun A, et al. Abstract P3-14-02: Incidence of venous thromboembolism in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibi- tors: A systematic review and meta- analysis of randomized controlled trials. In: Cancer Research. Vol 78. American Association for Cancer Research (AACR); 2018:P3-14-02-P3-14-02. DOI: 10.1158/1538- 7445.sabcs17-p3-14-02 12. Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol 2020;22(2):171-86. DOI: 10.1007/s12094- 019-02263-z 13. Spyropoulos AC, Eldredge JB, Anand LN, et al. External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS‐CAT Venous Thromboembolism Risk Assessment Model. Oncologist 2020;25:1-8. DOI: 10.1634/theonco- logist.2019-0482 14. Levine M, Hirsh J, Arnold A, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343(8902):886-9. DOI: 10.1016/S0140- 6736(94)90008-6 15. Haas SK, Freund M, Heigener D, et al. Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Throm- boembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer. Clin Appl Thromb Hemost 2012;18(2):159-65. DOI: 10.1177/1076029611433769 16. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the preven- tion of thromboembolic events in ambulatory patients with metas- tatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10(10):943-9. DOI: 10.1016/S1470-2045(09)70232-3 17. Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoa- gulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2019;17(10):1772-8. DOI: 10.1111/jth.14564 18. Mahé I, Chidiac J, Bertoletti L, et al. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. Am J Med 2017;130:337-47. DOI: 10.1016/j.amjmed.2016.10.017 19. Haemmerle M, Stone RL, Menter DG, et al. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 2018;33(6):965- 83. DOI: 10.1016/j.ccell.2018.03.002 20. Khan UT, Walker AJ, Baig S, et al. Venous thromboembolism and mortality in breast cancer: Cohort study with systematic review and meta-analysis. BMC Cancer 2017;17(1):747. DOI: 10.1186/s12885- 017-3719-1